Dysregulation of c-MYC is a hallmark of many human cancers, where its overexpression drives malignant transformation and tumor progression by activating a broad transcriptional network controlling ribosome biogenesis, nucleotide synthesis, and metabolic reprogramming (2). This evidence concerns the gene MYC and cancer.